NCT07908004
A Study to Test How Well Different Doses of BI 3821001 Are Tolerated by Healthy People
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator
Timeframe: Up to 81 days
Secondary (2)
Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)
Arms and interventions
BI 3821001 treatment groupExperimental
Placebo groupPlacebo comparator
Drugs: BI 3821001, Placebo
Sites
1 site in 1 country
- CRS Clinical Research Services Berlin GmbHBerlin, Germany